ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and pr
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG).